Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Potassium Phosphate→

Potassium Phosphate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7778-77-0
Molecular formula
H2KO4P
Molecular weight
136.086 g/mol
Drug class
Potassium phosphate saltelectrolyte and phosphate replacement agent
Mechanism of action
Dissociates to provide potassium and phosphate ions. Potassium supports membrane potential and cardiac conduction; phosphate is required for ATP, nucleic acids, phospholipids and intracellular buffering.
Indications / reported uses
  • Treatment of hypophosphataemia and selected combined potassium/phosphate depletion when intravenous replacement is indicated; monitor serum potassium, phosphate, calcium and renal function

Sources: US DailyMed — Potassium phosphate injection · NLM MeSH — Potassium phosphate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Potassium Phosphate Environmental Risk Assessment (ERA) (the Potassium Phosphate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.